WHO Expert Committee on Drug Dependence Pre-Review

Isomers of THC

Section 3: Toxicology

World Health Organization

This report contains the views of an international group of experts, and does not necessarily represent the decisions or the stated policy of the World Health Organization
This is an advance copy distributed to the participants of the 40th Expert Committee on Drug Dependence, before it has been formally published by the World Health Organization. The document may not be reviewed, abstracted, quoted, reproduced, transmitted, distributed, translated or adapted, in part or in whole, in any form or by any means without the permission of the World Health Organization.

The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

The World Health Organization does not warrant that the information contained in this publication is complete and correct and shall not be liable for any damages incurred as a result of its use.
Acknowledgments

This report was prepared by the Secretariat of the Expert Committee on Drug Dependence (ECDD) within the Department of Essential Medicines and Health Products (EMP) of the World Health Organization (WHO), Geneva, Switzerland. The WHO staff involved in the production of this document, developed under the overall guidance of Mariângela Simão (Assistant Director General, Access to Medicines, Vaccines, and Pharmaceuticals), Suzanne Hill (Director, Essential Medicines and Health Products), Gilles Forte, (Secretary of the Expert Committee on Drug Dependence) were Dilkushi Poovendran (Technical Officer, WHO Essential Medicines and Health Products) and Wil De Zwart (Technical Officer, WHO Essential Medicines and Health Products).

This report was commissioned as a background document for a preliminary review for the 40th Expert Committee on Drug Dependence (ECDD). WHO would like to acknowledge the contributions of the following individuals who authored this report:

Chemistry
Giuseppe Cannazza (University of Modena and Reggio Emilia), Italy
Cinzia Citti (University of Modena and Reggio Emilia), Italy

Pharmacology
Jenny Wiley (RTI International), USA

Epidemiology
Hayu Fernandez (Centre for Addiction and Mental Health), Canada
Vidhi Thakkar (Centre for Addiction and Mental Health), Canada
Omer S.M. Hasan (Centre for Addiction and Mental Health), Canada
Jakob Manthey (Institute for Clinical Psychology and Psychotherapy), Germany
Jurgen Rehm (Centre for Addiction and Mental Health), Canada
Astrid Otto (Centre for Addiction and Mental Health), Canada
Charlotte Probst (Centre for Addiction and Mental Health), Canada
Julian Sauer (Centre for Addiction and Mental Health), Canada

Toxicology
Jonathon Arnold (University of Sydney), Australia

Therapeutic Use
Kevin P. Hill (Harvard Medical School), USA
Judith Spahr, (Thomas Jefferson University) USA
Charles V. Pollack, (Thomas Jefferson University) USA
Brock Bakewell (Thomas Jefferson University), USA

The Member State questionnaire report was prepared by Jurgen Rehm, Astrid Otto, and Jakob Manthey. Technical editing was provided by Ann Morgan and Susan Kaplan. Administrative support was provided by Afrah Vogel and Christine Berling.
Contents

1. Toxicology .................................................................................................................. 5
   1.1 Δ8-THC ................................................................................................................. 5
   1.2 Δ6a,10a-THC ........................................................................................................ 6
   1.3 Δ9,11-THC ........................................................................................................... 6
   1.4 The remaining isomers ........................................................................................ 7

2. Adverse reactions in humans ...................................................................................... 8

3. References .................................................................................................................. 9
1. Toxicology

Very little information exists on the isomers of THC listed in Schedule 1 of the 1971 Convention on Psychotropic Substances, other than Δ⁸-THC which is found in the plant [1]. The other THC isomers do not have a botanical origin and were synthesised by medicinal chemists. As a general statement, toxicity of these isomers is very low. However, there is limited preclinical toxicity data on these isomers and they have not been administered to humans for extended periods of time.

1.1 Δ₈-THC

\((6aR,10aR)-6a,7,10a,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol\) is commonly known as Δ₈-THC (dibenzopyran numbering, Δ₀-THC in monoterpenoid numbering). Δ₈-THC binds the cannabinoid CB1 receptor and CB2 receptor with lower and higher affinity than Δ⁹-THC respectively [2]. It has considerably lower potency than Δ⁹-THC in the mouse tetrad test and unlike Δ⁹-THC, Δ₈-THC did not induce catalepsy or analgesic effects up to 20 mg/kg i.p. [2].

Lethality studies in animals show the doses of Δ₈-THC needed to induce death are well beyond that which could possibly be consumed by humans. To put this in perspective, the oral LD₅₀ for Δ₈-THC in rats is 2000 mg/kg [3, 4], which is higher than that found for Δ⁹-THC (800 mg/kg) [5]. In dogs the LD₃₀ of Δ₈-THC is greater than 3000 mg/kg [6].

Following oral administration or smoking, Δ₈-THC has approximately 50-75% the psychotropic potency of Δ⁹-THC [7-9]. Δ₈-THC slightly and transiently increases heart rate. Substantial subjective highs were noted at 20 - 40 mg oral doses, smoking doses of 5 - 20 mg and at i.v. doses of 1-9 mg.

Repeated Δ₈-THC dosing prior to conception or during gestation did not have teratogenic effects in rats (up to 40 mg/kg s.c.) [4]. There were no abnormalities in the F2 and F3 generations, although fertility may have been negatively impacted.

While limited data are available, Δ₈-THC does not appear to be mutagenic. Blood incubated with Δ₈-THC displayed decreased mitosis, although there were no histological abnormalities in the cells examined. Δ₈-THC did not cause any abnormalities in chromosome morphology or number - there were no breaks, gaps, lesions or aneuploidy observed [4, 10]. Δ₈-THC reduces the growth and proliferation of cancer cells in
culture (Lewis lung carcinoma and leukaemia cells) [4]. $\Delta^8$-THC has also been shown to reduce the proliferation of T and B lymphocytes and induce apoptosis, however this may bear little relevance to human plasma $\Delta^8$-THC concentrations attained following cannabis consumption [11].

1.2 $\Delta^{6a,10a}$-THC

- $7,8,9,10$-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol is also commonly referred to as $\Delta^{6a,10a}$-THC (dibenzopyran numbering, $\Delta^3$-THC in monoterpenoid numbering). $\Delta^{6a,10a}$-THC has low toxicity as it did not promote mortality following a dose of 200 mg/kg i.v. in mice [12].

$\Delta^{6a,10a}$-THC has much less pharmacological activity than $\Delta^9$-THC. An early pharmacological screen of cannabinoid activity was based on the ability of $\Delta^9$-THC to induce seizures in a subset of rabbits due to autosomal recessive mutation (THC-SS rabbits). Based on this screen it was shown that $\Delta^{6a,10a}$-THC was 15 times less potent than $\Delta^9$-THC [13]. In another study, the minimum effective dose of $\Delta^{6a,10a}$-THC required to reduce muricidal behaviour, an early model of CNS activity, was double that required with $\Delta^9$-THC [14]. $\Delta^{6a,10a}$-THC was inactive in reducing locomotor activity in mice, unlike $\Delta^9$-THC which promoted locomotor suppression.

$\Delta^{6a,10a}$-THC has been safely administered to humans via smoking, where it had much lower psychoactivity than $\Delta^9$-THC [15, 16]. The effects of smoking 15 mg $\Delta^{6a,10a}$-THC were less marked and shorter in duration than a 12 mg $\Delta^9$-THC dose. The participants experienced light-headedness, numbness and tingling in their extremities and face, fatigue, cold perspiration, drowsiness and a feeling of relaxation. Impairment in thinking and the perception of time were less pronounced than with $\Delta^9$-THC. Only 3 of the 6 participants displayed reddened conjunctivae. Although, other studies reported no effects of higher smoked doses of $\Delta^{6a,10a}$-THC [15, 16].

1.3 $\Delta^{9,11}$-THC

$(6aR,10aR)$-6a,7,8,9,10,10a-hexahydro-6,6-dimethyl-9-methylene-3-pentyl-6H-dibenzo[b,d]pyran-1-ol is also more commonly known as $\Delta^{9,11}$-THC (dibenzopyran numbering, $\Delta^{1,7}$-THC in monoterpenoid numbering). $\Delta^{9,11}$-THC has low toxicity with an i.v. LD$_{50}$ of 93 mg/kg in mice which is double that found for $\Delta^9$-THC [17]. It has considerably less pharmacological activity than $\Delta^9$-THC. Cannabinoid-like effects were observed with $\Delta^{9,11}$-THC in the tetrad test in mice, however much higher ED$_{50}$ doses were required to
reduce locomotor activity and tail-flick latency, and to induce hypothermia and catalepsy - Δ⁹,¹¹-THC was between 4 and 40 times less potent than Δ⁹-THC [18]. Δ⁹,¹¹-THC displaced CP 55,940 (a synthetic cannabinoid receptor agonist) from rat brain homogenates, indicating it binds cannabinoid receptors, albeit at a higher IC₅₀ than Δ⁹-THC (ie 334 versus 218 nM). Δ⁹,¹¹-THC however did not display Δ⁹-THC-like discriminative stimulus effects. Δ⁹,¹¹-THC has been administered i.v. to rhesus monkeys where unlike Δ⁹-THC it did not promote ptosis, ataxia or sedation [17]. It hasn’t been tested in humans, and high doses would be required to produce Δ⁹-THC-like intoxication [18].

1.4 The remaining isomers

(9R,10aR)-8,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol (Δ⁶a,⁷-THC or Δ⁴-THC), (6aR,9R,10aR)-6a,9,10,10a-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol (Δ⁷-THC or Δ⁵-THC) or 6a,7,8,9-tetrahydro-6,6,9-trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol (Δ¹⁰-THC or Δ²-THC) have not been assessed in any detail for their toxicity. Δ⁷-THC doesn’t appear to have activity in animal models [19]. The others may not have been tested for pharmacological activity.
2. Adverse reactions in humans

Only $\Delta^8$-THC and $\Delta^{6a,10a}$-THC have been tested in humans in pure form. As described above the acute intoxicating effects of these molecules was similar in quality but less potent than acute doses of $\Delta^9$-THC. These molecules are not available as recreational or therapeutic drugs, so we do not have a good understanding of their adverse effects in humans.
3. References


